NO20010922D0 - FremgangsmÕte for DNA vaksinering - Google Patents

FremgangsmÕte for DNA vaksinering

Info

Publication number: NO20010922D0
Authority: NO; Norway
Prior art keywords: compound; mammal; disease state; antigenic peptide; dna vaccination
Prior art date: 1998-08-26

Application number

NO20010922A

Other languages

English (en)

Other versions

NO20010922L (no

Inventor

Jehad Charo

Rolf Kiessling

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-26

Filing date

2001-02-23

Publication date

2001-02-23

2001-02-23 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2001-02-23 Publication of NO20010922D0 publication Critical patent/NO20010922D0/no

2001-04-23 Publication of NO20010922L publication Critical patent/NO20010922L/no

Links

238000000034 method Methods 0.000 title abstract 2
238000011238 DNA vaccination Methods 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
230000000890 antigenic effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 abstract 1
230000024932 T cell mediated immunity Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
230000028996 humoral immune response Effects 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229950009795 tucaresol Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20010922A 1998-08-26 2001-02-23 Fremgangsmåte for DNA vaksinering NO20010922L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9818627.3A GB9818627D0 (en)	1998-08-26	1998-08-26	Improvements in dva vaccination
PCT/EP1999/006217 WO2000012121A1 (en)	1998-08-26	1999-08-25	Method of dna vaccination

Publications (2)

Publication Number	Publication Date
NO20010922D0 true NO20010922D0 (no)	2001-02-23
NO20010922L NO20010922L (no)	2001-04-23

Family

ID=10837881

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20010922A NO20010922L (no)	1998-08-26	2001-02-23	Fremgangsmåte for DNA vaksinering

Country Status (22)

Country	Link
US (1)	US7074770B1 (no)
EP (1)	EP1107785B1 (no)
JP (1)	JP2002523469A (no)
KR (1)	KR20010072983A (no)
CN (1)	CN1326358A (no)
AT (1)	ATE411043T1 (no)
AU (1)	AU747643B2 (no)
BR (1)	BR9913323A (no)
CA (1)	CA2341544A1 (no)
CZ (1)	CZ2001717A3 (no)
DE (1)	DE69939747D1 (no)
ES (1)	ES2313791T3 (no)
GB (1)	GB9818627D0 (no)
HU (1)	HUP0103214A3 (no)
IL (1)	IL141623A0 (no)
NO (1)	NO20010922L (no)
NZ (1)	NZ510206A (no)
OA (1)	OA11644A (no)
PL (1)	PL346299A1 (no)
TR (1)	TR200101256T2 (no)
WO (1)	WO2000012121A1 (no)
ZA (1)	ZA200101539B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7223739B1 (en)	1995-06-07	2007-05-29	Powderject Vaccines, Inc.	Adjuvanted genetic vaccines
AU3593200A (en)	1999-02-09	2000-08-29	Powderject Vaccines, Inc.	(mycobacterium tuberculosis), immunization
GB9923309D0 (en) *	1999-10-01	1999-12-08	Glaxo Group Ltd	Assay
CN100333794C (zh) *	1999-11-03	2007-08-29	宝德杰克特疫苗有限公司	佐剂化的基因疫苗
EP1913957B1 (en) *	1999-11-03	2010-03-17	Powderject Vaccines, Inc.	Adjuvanted genetic vaccines
WO2001076626A2 (en) *	2000-04-11	2001-10-18	Galenica Pharmaceuticals, Inc.	Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
GB0023008D0 (en) *	2000-09-20	2000-11-01	Glaxo Group Ltd	Improvements in vaccination
US7538224B2 (en) *	2003-06-27	2009-05-26	Kyowa Hakko Kogyo Co., Ltd.	Hsp90 family protein inhibitors
CN100415876C (zh) *	2003-09-05	2008-09-03	杭州浙大康泰生物技术有限公司	艾滋病重组腺病毒疫苗
CN102770156B (zh)	2009-12-16	2016-01-20	克洛恩泰克制药股份公司	密码子优化的乙型肝炎病毒核心抗原(hbcag)
CA2839196A1 (en)	2011-06-15	2012-12-20	Chrontech Pharma Ab	Injection needle and device
EP3141542B1 (en)	2011-12-28	2020-05-27	Global Blood Therapeutics, Inc.	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
ES2790358T3 (es)	2011-12-28	2020-10-27	Global Blood Therapeutics Inc	Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
WO2014064534A2 (en)	2012-10-05	2014-05-01	Chrontech Pharma Ab	Injection needle, device, immunogenic compositions and method of use
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en)	2013-03-15	2015-10-29	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en)	2013-03-15	2018-10-16	Global Blood Therapeutics, Inc.	Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
MX2015011448A (es)	2013-03-15	2016-06-06	Global Blood Therapeutics Inc	Compuestos y sus usos para modular la hemoglobina.
ES2852054T3 (es)	2013-03-15	2021-09-10	Global Blood Therapeutics Inc	Compuestos y usos de los mismos para la modulación de hemoglobina
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru)	2013-11-18	2021-09-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
EP3868745A1 (en)	2014-02-07	2021-08-25	Global Blood Therapeutics, Inc.	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN107073119A (zh) *	2014-02-26	2017-08-18	德克萨斯大学***董事会	用于操控细胞酸中毒的硝基苯甲醛质子的释放
RU2736045C2 (ru)	2015-03-06	2020-11-11	Бейондспринг Фармасьютикалс, Инк.	Способ лечения рака, ассоциированного с мутацией ras
US11267807B2 (en) *	2015-10-28	2022-03-08	The Brigham And Women's Hospital, Inc.	Use of small molecule inhibitors to KLF10 for modulation of T regulatory cells and cancer immunotherapy
WO2017096230A1 (en)	2015-12-04	2017-06-08	Global Blood Therapeutics, Inc.	Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AU2017217426B2 (en)	2016-02-08	2022-12-01	Beyondspring Pharmaceuticals, Inc.	Compositions containing tucaresol or its analogs
TWI663160B (zh)	2016-05-12	2019-06-21	全球血液治療公司	用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TWI778983B (zh)	2016-10-12	2022-10-01	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN110431135A (zh)	2017-01-06	2019-11-08	大连万春布林医药有限公司	微管蛋白结合化合物及其治疗用途
EP3743074A4 (en)	2018-01-24	2021-12-15	Beyondspring Pharmaceuticals Inc.	COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
CN109232238B (zh) *	2018-08-29	2022-05-17	北京勤邦生物技术有限公司	吉非罗齐半抗原、人工抗原和抗体及其制备方法和用途
EP3860975B1 (en)	2018-10-01	2023-10-18	Global Blood Therapeutics, Inc.	Modulators of hemoglobin for the treatment of sickle cell disease
CN112778155B (zh) *	2019-11-11	2023-08-11	大连万春布林医药有限公司	妥卡雷琐衍生物及其用途
WO2022040719A1 (en) *	2020-08-26	2022-03-03	Gertrude Biomedical Pty Ltd	Antiviral sox inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5620896A (en) *	1992-03-23	1997-04-15	University Of Massachusetts Medical Center	DNA vaccines against rotavirus infections
ATE146075T1 (de) *	1992-10-01	1996-12-15	Wellcome Found	Tucaresol als mittel zur immunopotentierung
TW360548B (en) *	1993-04-08	1999-06-11	Powderject Res Ltd	Products for therapeutic use
CA2181832C (en)	1994-01-27	2012-11-27	Harriet L. Robinson	Immunization by inoculation of dna transcription unit

1998
- 1998-08-26 GB GBGB9818627.3A patent/GB9818627D0/en not_active Ceased
1999
- 1999-08-25 CA CA002341544A patent/CA2341544A1/en not_active Abandoned
- 1999-08-25 CN CN99812463A patent/CN1326358A/zh active Pending
- 1999-08-25 OA OA1200100050A patent/OA11644A/en unknown
- 1999-08-25 IL IL14162399A patent/IL141623A0/xx unknown
- 1999-08-25 PL PL99346299A patent/PL346299A1/xx not_active Application Discontinuation
- 1999-08-25 US US09/763,462 patent/US7074770B1/en not_active Expired - Fee Related
- 1999-08-25 KR KR1020017002431A patent/KR20010072983A/ko not_active Application Discontinuation
- 1999-08-25 HU HU0103214A patent/HUP0103214A3/hu unknown
- 1999-08-25 ES ES99944505T patent/ES2313791T3/es not_active Expired - Lifetime
- 1999-08-25 NZ NZ510206A patent/NZ510206A/en unknown
- 1999-08-25 DE DE69939747T patent/DE69939747D1/de not_active Expired - Lifetime
- 1999-08-25 CZ CZ2001717A patent/CZ2001717A3/cs unknown
- 1999-08-25 TR TR2001/01256T patent/TR200101256T2/xx unknown
- 1999-08-25 WO PCT/EP1999/006217 patent/WO2000012121A1/en not_active Application Discontinuation
- 1999-08-25 JP JP2000567235A patent/JP2002523469A/ja active Pending
- 1999-08-25 AT AT99944505T patent/ATE411043T1/de not_active IP Right Cessation
- 1999-08-25 BR BR9913323-7A patent/BR9913323A/pt not_active IP Right Cessation
- 1999-08-25 AU AU57402/99A patent/AU747643B2/en not_active Ceased
- 1999-08-25 EP EP99944505A patent/EP1107785B1/en not_active Expired - Lifetime
2001
- 2001-02-23 ZA ZA200101539A patent/ZA200101539B/en unknown
- 2001-02-23 NO NO20010922A patent/NO20010922L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2341544A1 (en)	2000-03-09
JP2002523469A (ja)	2002-07-30
NO20010922L (no)	2001-04-23
OA11644A (en)	2004-11-22
EP1107785A1 (en)	2001-06-20
TR200101256T2 (tr)	2001-10-22
BR9913323A (pt)	2001-12-04
KR20010072983A (ko)	2001-07-31
HUP0103214A3 (en)	2003-10-28
IL141623A0 (en)	2002-03-10
ATE411043T1 (de)	2008-10-15
ES2313791T3 (es)	2009-03-01
US7074770B1 (en)	2006-07-11
HUP0103214A2 (hu)	2001-12-28
PL346299A1 (en)	2002-01-28
ZA200101539B (en)	2002-02-25
GB9818627D0 (en)	1998-10-21
DE69939747D1 (de)	2008-11-27
AU5740299A (en)	2000-03-21
WO2000012121A1 (en)	2000-03-09
AU747643B2 (en)	2002-05-16
CZ2001717A3 (cs)	2001-10-17
CN1326358A (zh)	2001-12-12
EP1107785B1 (en)	2008-10-15
NZ510206A (en)	2003-08-29

Legal Events

Date	Code	Title	Description
2006-03-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20010922D0 (no)	2001-02-23	FremgangsmÕte for DNA vaksinering
US20070286871A1 (en)	2007-12-13	Vaccines
WO2003049762A3 (en)	2004-05-13	Immunisation against chlamydia trachomatis
BR9608615A (pt)	1999-06-15	Vacinas de vírus sincicial respiratório de ácido nucléico
DE60139690D1 (de)	2009-10-08	Immunisierung gegen chlamydia pneumoniae
EP0773295A3 (en)	1999-06-16	DNA-based vaccination of fish by immersion
AR035586A1 (es)	2004-06-16	Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
KR970707281A (ko)	1997-12-01	풀리뉴클레오티드 결핵 백신(A polynucleotide tuberculosis vaccine)
BR0108566A (pt)	2002-11-19	Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
NO20015073D0 (no)	2001-10-18	Vaksiner
BR9712971A (pt)	2002-05-07	Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica
AU7814498A (en)	1998-12-30	Multivalent (in ovo) avian vaccine
UA41381C2 (uk)	2001-09-17	Спосіб вакцинації птиці in ovo проти кокцидіозу
CN105377879A (zh)	2016-03-02	针对衣原体属物种的疫苗
CA2337754A1 (en)	2000-03-02	Recombinant multivalent malarial vaccine against plasmodium falciparum
ATE310747T1 (de)	2005-12-15	Impfstoff gegen geflügelkokzidose
DE69521007D1 (de)	2001-06-28	Impfstoff gegen Geflügelkokzidose
EA200301125A1 (ru)	2004-04-29	Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
Benhnini et al.	2009	Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains
CA2421580A1 (en)	2002-03-21	Discrimination between gnrh-i and gnrh-ii
WO2004100640A3 (en)	2006-01-19	Marek’s disease virus vaccine
EP0839913A3 (en)	1999-06-16	DNA-Based vaccination of fish by immersion
WO2002030458A8 (en)	2002-07-18	Yersinia adhesion protein as vaccine adjuvant
AU2579600A (en)	2000-08-18	Product and method for obtaining specific immunisation with one or more antigens
EP1502602A3 (en)	2006-05-17	Methods for therapeutic vaccination